Bowen Matthew 4

What Happened Matthew Bowen, Monte Rosa Therapeutics' Principal Accounting Officer, received equity awards on April 6, 2026: 4,300 restricted stock units (RSUs) and 19,500 derivative awards (reported with a $0.00 price). The RSUs represent contingent rights to receive common stock upon vesting; the 19,500 derivative awards appear as an option-type grant per the filing footnote. These are grants (code A), not open-market purchases or sales.

Key Details

• Transaction date: 2026-04-06; Form 4 filed: 2026-04-07 (timely; Form 4 is generally due within two business days).
• RSUs: 4,300 RSUs granted; acquisition price shown as N/A. Footnote F1: 25% vest on April 6, 2027, remainder vests in three equal annual installments thereafter, subject to continued service.
• Derivative award: 19,500 reported as acquired at $0.00 (total reported $0). Footnote F2: 25% vests/becomes exercisable on April 6, 2027; remaining vests in 36 substantially equal monthly installments, subject to continued service.
• Shares owned after transaction: not specified in the filing.
• Transaction code: A = award/grant. No 10b5-1, tax-withholding, or late-filing notes were indicated in the filing.

Context These entries are grants from the company’s equity plan and are common for employee compensation. RSUs convert to shares upon vesting; the 19,500 derivative units are subject to a vesting/exercisability schedule (not an immediate sale). Grants do not necessarily indicate the insider is buying or selling stock and should be interpreted as compensation unless later exercised or sold.